ESC Premium Access

Edoxaban versus warfarin in atrial fibrillation patients with low, mid and high body weight: analysis of outcomes in the engage af TIMI 48 trial

Congress Presentation

About the speaker

Professor Giuseppe Boriani

Modena Polyclinic Modena University Hospital, Modena (Italy)
52 presentations

7 more presentations in this session

Use of Non-vitamin K antagonist Oral Anticoagulants in a real-world setting: a community pharmacy-based study.

Speaker: Mr A. Capiau (Ghent, BE)


Potential real-world benefits of low-dose rivaroxaban in Chinese stable cardiovascular patients

Speaker: Associate Professor B. Yan (Hong Kong, CN)


Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study.

Speaker: Doctor M. Vedovati (Perugia, IT)


Risk of arterial calcification by conventional vitamin K antagonist treatment

Speaker: Doctor S. Hasific (Odense, DK)


Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation: Prospective KYU-RABLE study

Speaker: Professor N. Takahashi (Oita, JP)


Access the full session

Perspectives on anticoagulation across cardiovascular disease

Speakers: Professor G. Boriani, Mr A. Capiau, Associate Professor B. Yan, Doctor M. Vedovati, Doctor S. Hasific...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb